Mont. Code § 37-7-505

Current through the 2023 Regular Session
Section 37-7-505 - Product selection permitted - limitation
(1) Except as limited by subsection (2) and unless instructed otherwise by the purchaser:
(a) a pharmacist who receives a prescription for a specific drug product by brand or proprietary name may select a less expensive drug product with the same generic name, strength, quantity, dose, and dosage form as the prescribed drug that is, in the pharmacist's professional opinion, therapeutically equivalent, bioequivalent, and bioavailable; and
(b) a pharmacist who receives a prescription for a specific biological product may select a less expensive interchangeable biological product.
(2) If, in the professional opinion of the prescriber, it is medically necessary that an equivalent drug product or interchangeable biological product not be selected, the prescriber may so indicate by certifying that the specific brand-name drug product prescribed or the specific brand-name biological product prescribed is medically necessary for that particular patient. In the case of a prescription transmitted orally, the prescriber must expressly indicate to the pharmacist that the specific brand-name drug product prescribed or the specific biological product prescribed is medically necessary.
(3)
(a) Within 5 business days following the dispensing of a biological product, the dispensing pharmacist or the pharmacist's designee shall communicate the specific product provided to the patient, including the name of the product and the manufacturer, to the prescriber through any of the following electric records systems:
(i) an interoperable electronic medical records system;
(ii) an electronic prescribing technology;
(iii) a pharmacy benefit management system; or
(iv) a pharmacy record.
(b) Communication through an electronic records system as described in subsection (3)(a) is presumed to provide notice to the prescriber.
(c) If the pharmacist is unable to communicate pursuant to an electronic records system as provided in subsection (3)(a), the pharmacist shall communicate to the prescriber which biological product was dispensed to the patient using facsimile, telephone, electronic transmission, or other prevailing means.
(d) Communication is not required under this subsection (3) when:
(i) there is no federal food and drug administration approved interchangeable biological product for the product prescribed; or
(ii) a refill prescription is not changed from the product dispensed on the prior filling of the prescription.
(4) The pharmacist shall maintain a record of the biological product dispensed for at least 2 years.

§ 37-7-505, MCA

Amended by Laws 2017, Ch. 42,Sec. 3, eff. 10/1/2017.
En. 66-1530 by Sec. 3, Ch. 403, L. 1977; R.C.M. 1947, 66-1530; amd. Sec. 13, Ch. 388, L. 2001.